Descriptive Analysis of Clinical Outcomes in Patients With Prostate Gland Cancer, Which Spreads to Other Parts of the Body, Who Were Treated First With Novel Anti-hormone Therapy Followed by a Second Line Treatment With Novel Anti-Hormone Therapy or RadIum-223 (Xofigo).
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bayer
Age
Any age
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Patients with documented mCRPC receiving 1L NAHs.
Initiation of Ra-223 after 1L NAH therapy, or
Initiation of sequential NAH therapy after 1L NAH therapy
You may not be if
Patients involved in clinical trials
Patients who received combined therapies in 1L or 2L
Clareo Health | Descriptive Analysis of Clinical Outcomes in Patients With Prostate Gland Cancer, Which Spreads to Other Parts of the Body, Who Were Treated First With Novel Anti-hormone Therapy Followed by a Second Line Treatment With Novel Anti-Hormone Therapy or RadIum-223 (Xofigo).
